Chargement en cours...
RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study
INTRODUCTION: Rivaroxaban is a direct factor Xa inhibitor used once a day for prevention of thrombotic events in patients with atrial fibrillation (AF). However, in a small proportion of subjects thrombus in the left atrial appendage (LAA) is present despite this treatment. The aim of this study was...
Enregistré dans:
| Publié dans: | Arch Med Sci |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Termedia Publishing House
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7069443/ https://ncbi.nlm.nih.gov/pubmed/32190138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2019.86616 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|